Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
This is not a financial advice!
Recent block buy
Upcoming catalyst end of March 2024
Low float of 44.47M
Short float 11.20%
Keep an eye on 2.80 level - needs to get broken for a further upmove.
SL under 1.8
Potenential gap fill: TP approx. 14 -15
Most info on the chart.
Trade carefully!
This is not a financial advice!
Recent block buy
Upcoming catalyst end of March 2024
Low float of 44.47M
Short float 11.20%
Keep an eye on 2.80 level - needs to get broken for a further upmove.
SL under 1.8
Potenential gap fill: TP approx. 14 -15
Most info on the chart.
Trade carefully!
註釋
uhh it's getting hot交易結束：目標達成
booom what a trade!
Join Discord channel:
whop.com/marketplace/contingent-traders/
contingenttrader.com/
whop.com/marketplace/contingent-traders/
contingenttrader.com/
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
Join Discord channel:
whop.com/marketplace/contingent-traders/
contingenttrader.com/
whop.com/marketplace/contingent-traders/
contingenttrader.com/
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。